A small study analyzing use of rilonacept, an interleukin- 1 inhibitor, suggests that the agent may reduce gout flares during initiation of urate-lowering therapy, with a favorable safety profile. Those who received rilonacept had an average of 0.15 gout flares per patient, compared with 0.79 flare ups for those who received placebo.

Abstract: Arthritis & Rheumatism, January 4, 2012 (online).